ALS Blood‑Protein Panel Predicts Disease Onset Years Early
Researchers at the University of Miami analyzed longitudinal blood samples from the Pre‑fALS study, measuring more than 5,000 proteins in 516 plasma samples from 137 participants who carry ALS‑linked gene variants. Using artificial‑intelligence methods they identified a panel of 19 proteins that can forecast whether a carrier will develop amyotrophic lateral sclerosis and estimate the timing of onset. The panel predicted disease onset with an average error of about 1.6 years, outperforming the single marker neurofilament light chain (average error 2.4 years). Results were independently validated with data from the UK Biobank, confirming the pattern’s broader applicability. The study, published in Nature Medicine in July 2026, notes that the test is not yet ready for clinical deployment and will require further validation before routine laboratory use. Researchers are also evaluating whether the experimental drug tofersen can delay or prevent ALS when administered before symptoms appear, highlighting the potential of early‑intervention strategies.
The discovery offers a new molecular‑surveillance approach for families with inherited ALS risk, aiming to shift treatment from reactive symptom management to proactive, data‑driven timing of therapeutic trials.
Entities: Amyotrophic Lateral Sclerosis · Amyotrophic Lateral Sclerosis (ALS) · Nature Medicine · Neurofilament light chain (NEFL) · Pre‑fALS study · Pre‑symptomatic Familial ALS study · Tofersen · University of Miami
Claims
What the coverage asserts, and how well corroborated each claim is across sources.
- [● 5 SOURCES] A panel of 19 blood proteins can predict ALS onset in gene carriers. (Researchers at the University of Miami)
- [● 5 SOURCES] The study analyzed over 5,000 proteins in 516 plasma samples from 137 participants of the Pre‑fALS study. (Researchers)
- [● 5 SOURCES] The 19‑protein panel predicts disease onset with an average error of about 1.6 years, better than neurofilament light chain alone (2.4 years). (Study authors)
- [● 5 SOURCES] The protein panel is not yet ready for clinical use and requires further validation. (Authors)
- [● 5 SOURCES] Findings were validated using data from the UK Biobank. (Study authors)
- [● 4 SOURCES] Researchers are testing whether the drug tofersen can delay ALS if started before symptoms appear. (Study authors)
- [● 5 SOURCES] The study was published in Nature Medicine in July 2026. (Publication record)
- [● 5 SOURCES] Artificial‑intelligence methods were used to select the optimal protein combination. (Researchers)